Clinical Trials Browser

Terminated × Waldenstrom Macroglobulinemia × Everolimus × Clear all

NCT01125293 2021-04-23

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 1/2 Terminated

46 enrolled 29 charts

Waldenstrom Macroglobulinemia